July 21, 2008 — Velcura Therapeutics, Inc. CEO Michael Long, Ph.D., announced that William F. Brinkerhoff has joined the Board of Directors of the biotechnology company, which completed a first-in-man clinical trial for VEL-0230, a powerful anti-inflammatory agent that also stimulates bone formation and inhibits bone loss. Velcura is developing its lead compound as a treatment for rheumatoid arthritis and other bone diseases.

May 12, 2008 — Velcura Therapeutics Inc. announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis (RA) and other bone diseases. In extensive preclinical studies, VEL-0230 proved to be a powerful anti-inflammatory agent that also stimulates bone formation and inhibits bone loss. Taken together, these characteristics strongly suggest this drug may be an important therapy for RA patients.

May 9, 2008 — Dr. Michael W. Long recently was named the third-annual Grant Thornton Leader and Innovator of the Year. The “Leader & Innovator” award recognizes and rewards leaders and innovators in the state of Michigan who have demonstrated or created unique ideas, products or abilities that generate a better quality of life in our communities.

Feb. 8, 2008 — Velcura Therapeutics President and CEO Michael W. Long, PhD, announced his biotechnology company will work with Dr. Bob Sliskovic and International Discovery Sourcing Consultants, LLC (IDSC), on the design and sourcing of medicinal chemistry data for its second generation and new bone therapy molecules.

Jan. 28, 2008 — Velcura Therapeutics Inc., an early stage biotechnology company developing therapies for bone disease, recently completed a successful Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA). The IND enables Velcura to proceed with first-in-man clinical trials for its lead compound, VEL-0230.